Pacific Drilling Announces Third-Quarter 2019 Results
6.11.2019 06:08:00 EET | Business Wire | Press release
Pacific Drilling S.A. (NYSE: PACD) (“Pacific Drilling” or the “Company”) today reported results for the third quarter of 2019. Net loss for third-quarter 2019 was $90.8 million or $1.21 per diluted share, compared to net loss of $73.6 million or $0.98 per diluted share in second-quarter 2019.
Pacific Drilling CEO Bernie Wolford commented, “We continue to add meaningful backlog, demonstrating the strength of our marketing team, our reputation for high performance and the quality of our modern fleet. We are pleased to have the Pacific Khamsin committed through the end of the third-quarter 2020.”
Third-Quarter 2019 Operational and Financial Commentary
Third-quarter 2019 contract drilling revenue was $54.3 million, which included $3.1 million in reimbursable revenue. This compared to second-quarter 2019 contract drilling revenue of $76.4 million, which included $3.8 million in reimbursable revenue. The decrease in revenue resulted primarily from the Pacific Sharav completing its legacy Chevron five-year contract in late August 2019 and rolling over to continue working for Chevron at a lower dayrate reflective of the current market. Additionally, the Pacific Bora completed operations with ENI in Nigeria in July 2019.
Operating expenses for third-quarter 2019 were $60.3 million compared to $52.3 million in second-quarter 2019. The increase in operating expenses was primarily due to ramp-up costs as Pacific Khamsin prepares to commence its contract with Equinor in the U.S. Gulf of Mexico. Additionally, operating expenses included reimbursable revenue expenses for third-quarter 2019 of $2.6 million compared to $3.0 million in the second quarter of 2019.
General and administrative expenses for the third quarter of 2019 were $8.9 million, as compared to $10.0 million for the second quarter of 2019.
EBITDA(a) for third-quarter 2019 was $(14.3) million, compared to $14.0 million in second-quarter 2019 as a result of the decreases to revenue and increases to operating expenses described above.
Capital expenditures for the third quarter of 2019 were $9.7 million compared to $3.8 million in the second quarter of 2019. The increase in capital expenditures was primarily due to payments made to purchase a managed pressure drilling system.
Footnotes
|
(a) |
EBITDA and Adjusted EBITDA are non-GAAP financial measures. For a definition of EBITDA and Adjusted EBITDA and a reconciliation to net loss, please refer to the schedule included in this release. Management uses this operational metric to track company results and believes that this measure provides additional information that highlights the impact of our operating efficiency as well as the operating and support costs incurred in achieving the revenue performance. |
2019 Guidance
A schedule of Pacific Drilling’s updated 2019 guidance as of November 5, 2019 is available in the “Quarterly and Annual Results” subsection of the “Investor Relations” section of our website, www.pacificdrilling.com.
Conference Call
Pacific Drilling will conduct a conference call at 10 a.m. Central time on Wednesday, November 6, 2019 to discuss third-quarter 2019 results. To access the conference call, participants should contact the Conference Call Operator at +1 800-377-9510 within North America or +1 334-777-6978 outside of North America approximately 10 minutes prior to the scheduled start time and provide confirmation code #5137602. A replay of the call also will be available on the company’s website or by dialing +1 888-203-1112 within North America or +1 719-457-0820 outside of North America and providing confirmation code #5137602.
About Pacific Drilling
With its best-in-class drillships and highly experienced team, Pacific Drilling is committed to exceeding our customers’ expectations by delivering the safest, most efficient and reliable deepwater drilling services in the industry. Pacific Drilling’s fleet of seven drillships represents one of the youngest and most technologically advanced fleets in the world. Pacific Drilling has principal offices in Luxembourg and Houston. For more information about Pacific Drilling, including our current Fleet Status, please visit our website at www.pacificdrilling.com.
Forward-Looking Statements
Certain statements and information contained in this press release constitute “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and are generally identifiable by their use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “our ability to,” “may,” “plan,” “potential,” “predict,” “project,” “projected,” “should,” “will,” “would”, or other similar words which are not generally historical in nature. The forward-looking statements speak only as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise.
Our forward-looking statements express our current expectations or forecasts of possible future results or events, including future financial and operational performance and cash balances; revenue efficiency levels; market outlook; forecasts of trends; future client contract opportunities; future contract dayrates; our business strategies and plans or objectives of management; estimated duration of client contracts; backlog; expected capital expenditures; projected costs and savings; and the potential impact of our completed Chapter 11 proceedings on our future operations and ability to finance our business.
Although we believe that the assumptions and expectations reflected in our forward-looking statements are reasonable and made in good faith, these statements are not guarantees, and actual future results may differ materially due to a variety of factors. These statements are subject to a number of risks and uncertainties and are based on a number of judgments and assumptions as of the date such statements are made about future events, many of which are beyond our control. Actual events and results may differ materially from those anticipated, estimated, projected or implied by us in such statements due to a variety of factors, including if one or more of these risks or uncertainties materialize, or if our underlying assumptions prove incorrect.
Important factors that could cause actual results to differ materially from our expectations include: the global oil and gas market and its impact on demand for our services; the offshore drilling market, including reduced capital expenditures by our clients; changes in worldwide oil and gas supply and demand; rig availability and supply and demand for high-specification drillships and other drilling rigs competing with our fleet; our ability to enter into and negotiate favorable terms for new drilling contracts or extensions; our ability to successfully negotiate and consummate definitive contracts and satisfy other customary conditions with respect to letters of intent and letters of award that we receive for our drillships; possible cancellation, renegotiation, termination or suspension of drilling contracts as a result of mechanical difficulties, performance, market changes or other reasons; costs related to stacking of rigs; downtime and other risks associated with offshore rig operations, including unscheduled repairs or maintenance, relocations, severe weather or hurricanes; our small fleet and reliance on a limited number of clients; our ability to execute our business plans; the effects of our completed Chapter 11 proceedings on our future operations; and the other risk factors described in our 2018 Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2019 and our Reports on Form 6-K. These documents are available through our website at www.pacificdrilling.com or through the SEC’s website at www.sec.gov.
|
PACIFIC DRILLING S.A. AND SUBSIDIARIES |
||||||||||||||||||
|
Condensed Consolidated Statements of Operations |
||||||||||||||||||
|
(in thousands, except per share information) (unaudited) |
||||||||||||||||||
|
|
||||||||||||||||||
|
|
|
Successor |
|
|
Predecessor |
|
Successor |
|
|
Predecessor |
|
|||||||
|
|
|
Three Months |
|
Three Months |
|
|
Three Months |
|
Nine Months |
|
|
Nine Months |
|
|||||
|
|
|
Ended |
|
Ended |
|
|
Ended |
|
Ended |
|
|
Ended |
|
|||||
|
|
|
September 30, |
|
June 30, |
|
|
September 30, |
|
September 30, |
|
|
September 30, |
|
|||||
|
|
|
2019 |
|
2019 |
|
|
2018 |
|
2019 |
|
|
2018 |
|
|||||
|
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contract drilling |
|
$ |
54,315 |
|
$ |
76,415 |
|
|
$ |
56,673 |
|
$ |
196,646 |
|
|
$ |
205,306 |
|
|
Costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
(60,324) |
|
|
(52,254) |
|
|
|
(44,234) |
|
|
(164,874) |
|
|
|
(164,556) |
|
|
General and administrative expenses |
|
|
(8,855) |
|
|
(10,010) |
|
|
|
(10,947) |
|
|
(30,111) |
|
|
|
(41,032) |
|
|
Depreciation and amortization expense |
|
|
(47,734) |
|
|
(59,330) |
|
|
|
(70,125) |
|
|
(165,963) |
|
|
|
(210,115) |
|
|
|
|
|
(116,913) |
|
|
(121,594) |
|
|
|
(125,306) |
|
|
(360,948) |
|
|
|
(415,703) |
|
|
Operating loss |
|
|
(62,598) |
|
|
(45,179) |
|
|
|
(68,633) |
|
|
(164,302) |
|
|
|
(210,397) |
|
|
Other income (expense) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(24,459) |
|
|
(24,406) |
|
|
|
(45,446) |
|
|
(72,904) |
|
|
|
(77,586) |
|
|
Reorganization items |
|
|
(24) |
|
|
(878) |
|
|
|
(30,599) |
|
|
(1,905) |
|
|
|
(56,108) |
|
|
Interest income |
|
|
1,510 |
|
|
1,665 |
|
|
|
1,019 |
|
|
5,147 |
|
|
|
2,720 |
|
|
Equity earnings in unconsolidated subsidiaries |
|
|
22 |
|
|
(263) |
|
|
|
— |
|
|
(1,293) |
|
|
|
— |
|
|
Expenses to unconsolidated subsidiaries, net |
|
|
(510) |
|
|
(437) |
|
|
|
— |
|
|
(1,219) |
|
|
|
— |
|
|
Other expense |
|
|
(409) |
|
|
(220) |
|
|
|
(923) |
|
|
(720) |
|
|
|
(2,254) |
|
|
Loss before income taxes |
|
|
(86,468) |
|
|
(69,718) |
|
|
|
(144,582) |
|
|
(237,196) |
|
|
|
(343,625) |
|
|
Income tax expense |
|
|
(4,315) |
|
|
(3,868) |
|
|
|
(201) |
|
|
(11,152) |
|
|
|
(953) |
|
|
Net loss |
|
$ |
(90,783) |
|
$ |
(73,586) |
|
|
$ |
(144,783) |
|
$ |
(248,348) |
|
|
$ |
(344,578) |
|
|
Loss per common share, basic |
|
$ |
(1.21) |
|
$ |
(0.98) |
|
|
$ |
(6.78) |
|
$ |
(3.31) |
|
|
$ |
(16.13) |
|
|
Weighted average shares outstanding, basic |
|
|
75,005 |
|
|
75,001 |
|
|
|
21,368 |
|
|
75,012 |
|
|
|
21,357 |
|
|
Loss per common share, diluted |
|
$ |
(1.21) |
|
$ |
(0.98) |
|
|
$ |
(6.78) |
|
$ |
(3.31) |
|
|
$ |
(16.13) |
|
|
Weighted average shares outstanding, diluted |
|
|
75,005 |
|
|
75,001 |
|
|
|
21,368 |
|
|
75,012 |
|
|
|
21,357 |
|
|
PACIFIC DRILLING S.A. AND SUBSIDIARIES |
||||||||||
|
Condensed Consolidated Balance Sheets |
||||||||||
|
(in thousands) (unaudited) |
||||||||||
|
|
||||||||||
|
|
|
September 30, |
|
June 30, |
|
December 31, |
|
|||
|
|
|
2019 |
|
2019 |
|
2018 |
|
|||
|
Assets: |
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
355,906 |
|
$ |
305,488 |
|
$ |
367,577 |
|
|
Restricted cash |
|
|
6,076 |
|
|
8,500 |
|
|
21,498 |
|
|
Accounts receivable, net |
|
|
29,751 |
|
|
65,403 |
|
|
40,549 |
|
|
Other receivable |
|
|
— |
|
|
28,000 |
|
|
28,000 |
|
|
Materials and supplies |
|
|
43,986 |
|
|
42,441 |
|
|
40,429 |
|
|
Prepaid expenses and other current assets |
|
|
11,685 |
|
|
14,916 |
|
|
9,149 |
|
|
Total current assets |
|
|
447,404 |
|
|
464,748 |
|
|
507,202 |
|
|
Property and equipment, net |
|
|
1,860,724 |
|
|
1,878,848 |
|
|
1,915,172 |
|
|
Receivable from unconsolidated subsidiaries |
|
|
204,790 |
|
|
204,790 |
|
|
204,790 |
|
|
Intangible asset |
|
|
— |
|
|
20,640 |
|
|
85,053 |
|
|
Investment in unconsolidated subsidiaries |
|
|
11,400 |
|
|
11,234 |
|
|
11,876 |
|
|
Other assets |
|
|
22,252 |
|
|
30,014 |
|
|
24,120 |
|
|
Total assets |
|
$ |
2,546,570 |
|
$ |
2,610,274 |
|
$ |
2,748,213 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and shareholders’ equity: |
|
|
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
12,009 |
|
$ |
17,835 |
|
$ |
14,941 |
|
|
Accrued expenses |
|
|
20,292 |
|
|
18,327 |
|
|
25,744 |
|
|
Accrued interest |
|
|
31,406 |
|
|
15,703 |
|
|
16,576 |
|
|
Deferred revenue, current |
|
|
5,931 |
|
|
1,298 |
|
|
— |
|
|
Total current liabilities |
|
|
69,638 |
|
|
53,163 |
|
|
57,261 |
|
|
Long-term debt |
|
|
1,064,643 |
|
|
1,056,037 |
|
|
1,039,335 |
|
|
Payable to unconsolidated subsidiaries |
|
|
4,194 |
|
|
3,741 |
|
|
4,400 |
|
|
Other long-term liabilities |
|
|
33,143 |
|
|
33,528 |
|
|
28,259 |
|
|
Total liabilities |
|
|
1,171,618 |
|
|
1,146,469 |
|
|
1,129,255 |
|
|
Shareholders’ equity: |
|
|
|
|
|
|
|
|
|
|
|
Common shares |
|
|
751 |
|
|
750 |
|
|
750 |
|
|
Additional paid-in capital |
|
|
1,650,685 |
|
|
1,648,756 |
|
|
1,645,692 |
|
|
Treasury shares, at cost |
|
|
(652) |
|
|
(652) |
|
|
— |
|
|
Accumulated deficit |
|
|
(275,832) |
|
|
(185,049) |
|
|
(27,484) |
|
|
Total shareholders’ equity |
|
|
1,374,952 |
|
|
1,463,805 |
|
|
1,618,958 |
|
|
Total liabilities and shareholders’ equity |
|
$ |
2,546,570 |
|
$ |
2,610,274 |
|
$ |
2,748,213 |
|
|
PACIFIC DRILLING S. A. AND SUBSIDIARIES |
||||||||
|
Condensed Consolidated Statements of Cash Flows |
||||||||
|
(in thousands) (unaudited) |
||||||||
|
|
||||||||
|
|
|
Successor |
|
|
Predecessor |
|
||
|
|
|
Nine Months |
|
|
Nine Months |
|
||
|
|
|
Ended September 30, |
|
|
Ended September 30, |
|
||
|
|
|
2019 |
|
|
2018 |
|
||
|
|
|
|
|
|
|
|
|
|
|
Cash flow from operating activities: |
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(248,348) |
|
|
$ |
(344,578) |
|
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
|
|
|
Depreciation and amortization expense |
|
|
165,963 |
|
|
|
210,115 |
|
|
Amortization of deferred revenue |
|
|
(1,513) |
|
|
|
(17,322) |
|
|
Amortization of deferred costs |
|
|
879 |
|
|
|
12,237 |
|
|
Amortization of debt premium, net |
|
|
(330) |
|
|
|
— |
|
|
Interest paid-in-kind |
|
|
25,638 |
|
|
|
456 |
|
|
Deferred income taxes |
|
|
7,157 |
|
|
|
(3,069) |
|
|
Share-based compensation expense |
|
|
5,076 |
|
|
|
1,611 |
|
|
Reorganization items |
|
|
— |
|
|
|
22,270 |
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
38,798 |
|
|
|
5,932 |
|
|
Materials and supplies |
|
|
(3,557) |
|
|
|
3,033 |
|
|
Prepaid expenses and other assets |
|
|
(7,972) |
|
|
|
6,292 |
|
|
Accounts payable and accrued expenses |
|
|
16,729 |
|
|
|
10,712 |
|
|
Deferred revenue |
|
|
7,444 |
|
|
|
(481) |
|
|
Net cash provided by (used in) operating activities |
|
|
5,964 |
|
|
|
(92,792) |
|
|
Cash flow from investing activities: |
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
(31,108) |
|
|
|
(15,080) |
|
|
Net cash used in investing activities |
|
|
(31,108) |
|
|
|
(15,080) |
|
|
Cash flow from financing activities: |
|
|
|
|
|
|
|
|
|
Payments for shares issued under share-based compensation plan |
|
|
(82) |
|
|
|
(4) |
|
|
Proceeds from debtor-in-possession financing |
|
|
— |
|
|
|
50,000 |
|
|
Proceeds from long-term debt |
|
|
— |
|
|
|
1,000,000 |
|
|
Payments for financing costs |
|
|
(1,215) |
|
|
|
(27,422) |
|
|
Purchases of treasury shares |
|
|
(652) |
|
|
|
— |
|
|
Net cash provided by (used in) financing activities |
|
|
(1,949) |
|
|
|
1,022,574 |
|
|
Net increase (decrease) in cash and cash equivalents |
|
|
(27,093) |
|
|
|
914,702 |
|
|
Cash, cash equivalents and restricted cash, beginning of period |
|
|
389,075 |
|
|
|
317,448 |
|
|
Cash, cash equivalents and restricted cash, end of period |
|
$ |
361,982 |
|
|
$ |
1,232,150 |
|
EBITDA and Adjusted EBITDA Reconciliation
EBITDA is defined as earnings before interest expense, taxes, depreciation and amortization. Adjusted EBITDA is defined as earnings before interest expense, taxes, depreciation, amortization, equity earnings in unconsolidated subsidiaries, expenses to unconsolidated subsidiaries, net and reorganization items. EBITDA and Adjusted EBITDA do not represent and should not be considered an alternative to net income, operating income, cash flow from operations or any other measure of financial performance presented in accordance with U.S. generally accepted accounting principles (“GAAP”) and our calculation of EBITDA and Adjusted EBITDA may not be comparable to that reported by other companies. EBITDA and Adjusted EBITDA are included herein because they are used by management to measure the Company’s operations. Management believes that EBITDA and Adjusted EBITDA present useful information to investors regarding the Company’s operating performance.
|
PACIFIC DRILLING S.A. AND SUBSIDIARIES |
||||||||||||||||||
|
Supplementary Data—Reconciliation of Net Loss to Non-GAAP EBITDA and Adjusted EBITDA |
||||||||||||||||||
|
(in thousands) (unaudited) |
||||||||||||||||||
|
|
||||||||||||||||||
|
|
|
Successor |
|
|
Predecessor |
|
Successor |
|
|
Predecessor |
|
|||||||
|
|
|
Three Months |
|
Three Months |
|
|
Three Months |
|
Nine Months |
|
|
Nine Months |
|
|||||
|
|
|
Ended |
|
Ended |
|
|
Ended |
|
Ended |
|
|
Ended |
|
|||||
|
|
|
September 30, |
|
June 30, |
|
|
September 30, |
|
September 30, |
|
|
September 30, |
|
|||||
|
|
|
2019 |
|
2019 |
|
|
2018 |
|
2019 |
|
|
2018 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(90,783) |
|
$ |
(73,586) |
|
|
$ |
(144,783) |
|
$ |
(248,348) |
|
|
$ |
(344,578) |
|
|
Add: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
24,459 |
|
|
24,406 |
|
|
|
45,446 |
|
|
72,904 |
|
|
|
77,586 |
|
|
Depreciation and amortization expense |
|
|
47,734 |
|
|
59,330 |
|
|
|
70,125 |
|
|
165,963 |
|
|
|
210,115 |
|
|
Income tax expense |
|
|
4,315 |
|
|
3,868 |
|
|
|
201 |
|
|
11,152 |
|
|
|
953 |
|
|
EBITDA |
|
$ |
(14,275) |
|
$ |
14,018 |
|
|
$ |
(29,011) |
|
$ |
1,671 |
|
|
$ |
(55,924) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Add: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity earnings in unconsolidated subsidiaries |
|
|
(22) |
|
|
263 |
|
|
|
— |
|
|
1,293 |
|
|
|
— |
|
|
Expenses to unconsolidated subsidiaries, net |
|
|
510 |
|
|
437 |
|
|
|
— |
|
|
1,219 |
|
|
|
— |
|
|
Reorganization items |
|
|
24 |
|
|
878 |
|
|
|
30,599 |
|
|
1,905 |
|
|
|
56,108 |
|
|
Adjusted EBITDA |
|
$ |
(13,763) |
|
$ |
15,596 |
|
|
$ |
1,588 |
|
$ |
6,088 |
|
|
$ |
184 |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105006308/en/
Contact information
Investor Contact:
James Harris
Pacific Drilling S.A.
+713 334 6662
Investor@pacificdrilling.com
Media Contact:
Amy Roddy
Pacific Drilling S.A.
+713 334 6662
Media@pacificdrilling.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
